Stock Events

Stock Events

Helus Pharma 

€4.51
0
+€0.11+2.5% Today

Statistics

Day High
4.58
Day Low
4.34
52W High
7.7
52W Low
3.7
Volume
3,861
Avg. Volume
1,178
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1JulExpected
Q4 2025
Next
-0.84
-0.77
-0.71
-0.64
Expected EPS
-0.6656585247783792
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow R7E.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap712.95M
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Cybin's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap1.33B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor to Cybin.
GH Research
GHRS
Mkt Cap975.1M
GH Research is involved in the development of therapeutics based on DMT for depression, competing in the same psychedelic treatment space as Cybin.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including psilocybin and MDMA, competing in the mental health treatment market alongside Cybin.
Revive Therapeutics
RVVTF
Mkt Cap12.63M
Revive Therapeutics is exploring the use of psychedelics for the treatment of various conditions, including mental health disorders, making it a competitor to Cybin.
PSYC
PSYC
Mkt Cap135,518
Psyched Wellness is focused on the development of psychedelic products, including Amanita Muscaria, competing in the broader psychedelic wellness market.
TripAdvisor
TRIP
Mkt Cap1.28B
Red Light Holland is involved in the production, growth, and sale of a premium brand of magic truffles, competing in the psychedelic substances market relevant to Cybin's interests.

About

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Show more...
CEO
Mr. Eric So L.L.B.
Employees
50
Country
Canada
ISIN
CA23256X4075

Listings

STU
DE
R7E.STU
MU
DE
R7E.MU
XNAS
US
HELP
F
DE
R7E.F

0 Comments

Share your thoughts

FAQ

What is Helus Pharma stock price today?▼
The current price of R7E.STU is €4.51 EUR — it has increased by +2.5% in the past 24 hours. Watch Helus Pharma stock price performance more closely on the chart.
What is Helus Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Helus Pharma stocks are traded under the ticker R7E.STU.
Is Helus Pharma stock price growing?▼
R7E.STU stock has risen by +1.93% compared to the previous week, the month change is a +8.33% rise, over the last year Helus Pharma has showed a -12.06% decrease.
When is the next Helus Pharma earnings date?▼
Helus Pharma is going to release the next earnings report on July 01, 2026.
What were Helus Pharma earnings last quarter?▼
R7E.STU earnings for the last quarter are -0.84 EUR per share, whereas the estimation was -0.64 EUR resulting in a -30.53% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Helus Pharma have?▼
As of April 13, 2026, the company has 50 employees.
In which sector is Helus Pharma located?▼
Helus Pharma operates in the Health & Wellness sector.
When did Helus Pharma complete a stock split?▼
Helus Pharma has not had any recent stock splits.
Where is Helus Pharma headquartered?▼
Helus Pharma is headquartered in Toronto, Canada.